1997 · Devices & clinical
Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and central nervous system disorders
Malek AM, Connors S, Robertson RL, Folkman J, Scott RM.
Pediatr Neurosurg 27(4):182-9, 1997.
PMID 9577971 · DOI 10.1159/000121249
In plain language
Moyamoya is a disease in which major arteries at the base of the brain narrow and close, and many new vessels form to compensate. Basic fibroblast growth factor (bFGF), a protein that encourages new vessel growth, has been proposed as a driver of this response.
The authors measured bFGF in cerebrospinal fluid, the fluid around the brain and spinal cord collected during surgery, mostly from children. Levels were significantly higher in moyamoya (141 pg/ml, 37 patients), Chiari malformation, tethered cord, arteriovenous malformation and brain tumor than in hydrocephalus (5.5 pg/ml) and controls (1.6 pg/ml). In moyamoya, higher levels showed a trend toward more new vessel growth after synangiosis, a surgery that encourages a new blood supply to the brain.
bFGF is not specific to moyamoya but may weakly predict how much new vessel growth to expect after such surgery.
A plain-language summary for patients and families. It is not medical advice, and individual results vary.
Abstract
Moyamoya syndrome is a vaso-occlusive disease involving the intracranial vessels of the circle of Willis which is accompanied by an intense compensatory recruitment of new vessels. Angiogenic substances such as basic fibroblast growth factor (bFGF) present in the cerebrospinal fluid (CSF) have been proposed as possible mediators of the neovascular response. We analyzed CSF samples collected intraoperatively from predominantly pediatric patients with moyamoya and other conditions such as Chiari malformation (Ch), tethered cord (TC), arteriovenous malformation (AVM), brain tumor (BT) and hydrocephalus (HCP). We found that CSF bFGF was significantly elevated in patients with moyamoya (141 pg/ml, n = 37), Ch (56.7 pg/ml, n = 22), TC (55.1 pg/ml, n = 23), AVM (354 pg/ml, n = 5), and BT (208 pg/ml, n = 5) compared to patients with HCP (5.5 pg/ml, n = 7) and controls (1.6 pg/ml, n = 25; p < 0.05). There was no dependence of CSF bFGF on patient age or gender. Although CSF bFGF in the moyamoya group showed no correlation with the Suzuki radiographic stage at either pre- or post-operative (1-year follow-up) angiography, it showed a trend with the Matsushima angiographic score with increasing collateral vascularization from the synangiosis developing at higher levels of CSF bFGF. Our findings suggest that CSF bFGF may be playing a wide-ranging role in a number of central nervous system conditions associated with ischemia and hypervascularity. Although not a specific marker for moyamoya, elevated CSF bFGF may serve as a weak predictor of the extent of angiogenesis to be expected in indirect revascularization procedures.
Abstract as indexed in PubMed (PMID 9577971). Copyright the publisher.
Cite this paper
Malek AM, Connors S, Robertson RL, Folkman J, Scott RM. Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and central nervous system disorders. Pediatr Neurosurg 27(4):182-9. 1997. doi:10.1159/000121249 PMID: 9577971.